Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity
Haploidentical allogeneic hematopoietic stem cell transplantation (h-HSCT) is increasingly used in patients lacking an HLA-matched donor. In this context, the combination of posttransplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) effectively prevents graft-versus-host disease, but its impact on the reconstitution of peripheral blood natural killer (NK) cell subsets remains insufficiently characterized. In this study, NK cell subsets were analyzed in depth in 56 adult recipients of unmanipulated h-HSCT with PTCy and ATG. Peripheral blood samples were collected at days +30, +60, and +100 after transplant. NK cell immunophenotype and cytotoxic function were assessed using multiparameter flow cytometry with unsupervised clustering, and degranulation assays against lymphoid and myeloid targets. Data were compared with those from 200 healthy volunteers. In spite of early numerical reconstitution, NK cells exhibited an immature immunophenotype with a low expression of activation markers. Cytotoxic activity against lymphoid targets was preserved, but degranulation against acute myeloid leukemia cell lines was significantly impaired across all NK subsets, including phenotypically mature NK cells. Cytomegalovirus reactivation was associated with an expansion of memory-like NK subsets but did not enhance degranulation. Functional education via killer cell immunoglobulin-like receptors was lost by day +30 and progressively reacquired from day +60 onward, in a pattern primarily influenced by the HLA-C genotype of recipients. These results indicate that, after h-HSCT with PTCy and ATG, NK cell subsets recover in number but fail to achieve early functional competence, particularly against myeloid targets. Strategies aiming at restoring mature NK cell functions warrant prospective investigations, especially in high-risk myeloid malignancies.
Authors
- Sophie Vantyghem
- E Ferron (ORCID: https://orcid.org/0009-0007-4029-9210)
- Thierry Guillaume (ORCID: https://orcid.org/0000-0001-5482-8565)
- Christelle Retière (ORCID: https://orcid.org/0000-0001-5943-6990)
- Alix Duquesne
- Pierre Péterlin (ORCID: https://orcid.org/0000-0001-5463-6686)
- Maxime Jullien (ORCID: https://orcid.org/0000-0001-6915-6570)
- Patrice Chevallier (ORCID: https://orcid.org/0000-0003-3142-5581)
- Katia Gagne (ORCID: https://orcid.org/0000-0002-4467-5961)
- Alice Garnier
- Nolwenn Legrand
- Catherine Willem
- Simon Bouzy
- Mathilde Bastien (ORCID: https://orcid.org/0009-0006-0975-0440)
- Gaëlle David
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- Services déconcentrés d'appui à la recherche Pays de la Loire (FR)
- Laboratoire de Thermique et Energie de Nantes (FR)
- Établissement Français du Sang (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1182/bloodadvances.2025017707
- Citations
- 1
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Institut National de la Santé et de la Recherche Médicale
- Ligue Contre le Cancer
- Etablissement Français du Sang